Esperion Therapeutics Bolsa (NASDAQ: ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Bolsa, Quote.MetaTitle.unusual-options

Esperion Therapeutics

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRIT HLDGS S/ADR NEW by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HOLDINGS LTD NEW by Esprit Holdings Ltd.

Esprit Holdings Ltd ADR

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Cormedix

Cronos Group

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Oculis Holding

Omeros

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Ventyx Biosciences

Zevra Therapeutics

Esperion Therapeutics (ESPR) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Comments

Esperion Therapeutics Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL